Limited Competition: Continuation of the Center for Genomic Studies on Mental Disorders (U24 Clinical Trial Not Allowed)
Funding Opportunity RFA-MH-20-215 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Institute of Mental Health (NIMH) seeks applications to develop, sustain, enhance, and enrich a centralized national biorepository for genetic studies of psychiatric disorders for facilitation and acceleration of the scientific understanding of the genetic risk architecture underlying mental disorders. This effort is expected to involve a functionally integrated, multi-disciplinary team that will provide for open sharing of biosamples and data resources through a single, centrali...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 11, 2019 Category: Research Source Type: funding

Clinical Studies of Mental Illness (Collaborative R01 Clinical Trial Optional)
Funding Opportunity PAR-19-297 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, not involving treatment development, efficacy, or effectiveness trials. Primary areas of focus include mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology) also when associated with HIV/AIDS. Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the s...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 10, 2019 Category: Research Source Type: funding

Pediatric Cardiac Genomics Consortium (U01 - Clinical Trial Not Allowed)
Funding Opportunity RFA-HL-20-015 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications to participate as a Research Center in the Pediatric Cardiac Genomics Consortium (PCGC) (http://www.benchtobassinet.com/). The PCGCs mission is to identify genetic causes of human congenital heart disease (CHD) and to relate genetic variants in patients with CHD to clinical outcomes through collaborative, multi-center studies. The PCGC fosters investigation along the translational spectrum of CHD research through interactions with Cardiovascular Development Dat...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 6, 2019 Category: Research Source Type: funding

Cardiovascular Developmental Biology Data Resource Center (U01 - Clinical Trial Not Allowed)
The objective of this FOA is to support the development of the Data Resource Center for the basic science component of the NHLBI Bench to Bassinet (B2B) Program. The goal of the Data Resource Center is to accelerate discovery of genetic etiology and biologic pathways associated with cardiovascular development and congenital heart disease by facilitating access to and querying of annotated data from cardiovascular development studies. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 6, 2019 Category: Research Source Type: funding

Postdoctoral Research Associate Training (PRAT) Program (Fi2)
Funding Opportunity PAR-19-286 from the NIH Guide for Grants and Contracts. The NIGMS Postdoctoral Research Associate Training (PRAT) Programs overarching goal is to provide high quality postdoctoral research training in the basic biomedical sciences to a diverse group of postdoctoral fellows in NIH Intramural research laboratories, and to prepare them for leadership positions in biomedical careers. Research projects proposed should focus on areas within the NIGMS mission, which include but are not limited to biological chemistry, biophysics, bioinformatics, cellular and molecular biology, computational biosciences, devel...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 21, 2019 Category: Research Source Type: funding

Centers Without Walls for Collaborative Research in the Epilepsies: Functional Evaluation of Human Genetic Variants (U54 Clinical Trial Not Allowed)
Funding Opportunity RFA-NS-19-019 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement (U54) applications from multidisciplinary groups of investigators to accelerate the rate of progress in determining the functional, pharmacological, neuronal network and whole animal consequences of genetic variants discovered in patients with various types of epilepsy and to develop strategies for establishing diagnostic criteria and identifying potential targets for intervention. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 13, 2019 Category: Research Source Type: funding

Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional)
Funding Opportunity PAR-19-277 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages the submission of exploratory/developmental research grant (R21) applications for cancer epidemiologic research. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as improving data collection methods, developing and validating methods of exposures and biological effects, such as epigenetics and metabolomics, and their applicat...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 8, 2019 Category: Research Source Type: funding

Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-278 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to support projects which exploit genome or epigenome editing to functionally validate and characterize genes or variants involved in substance use disorder-relevant phenotypes. It is expected that any genetic resources generated will be made broadly available to the scientific community to enable investigation of the relevant neurobiological mechanisms involved and provide critical foundational knowledge for the development of future prevention, diagnostic, and therapeutic strategies. (Source: NIH Funding Opportu...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 8, 2019 Category: Research Source Type: funding

The NIGMS Human Genetic Cell Repository (U42 - Clinical Trial Not Allowed)
Funding Opportunity RFA-GM-19-002 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support the NIGMS Human Genetic Cell Repository (HGCR). The repository will maintain the current collection of cell cultures and DNA samples and will acquire, characterize, and expand high-quality cell samples, and distribute cell lines and DNA isolated from them to qualified biomedical researchers. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 7, 2019 Category: Research Source Type: funding

Cognitive Systems Analysis of Alzheimer's Disease Genetic and Phenotypic Data (U01 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-269 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that propose Artificial Intelligence (AI), Machine Learning (ML), and/or Deep Learning (DL) approaches, collectively referred to here as "cognitive systems," that lead to the identification of gene mutations/variants that cause or contribute to the risk of or protection against the development of Alzheimers disease (AD) and Alzheimer's disease related dementias (ADRD) via analysis of a variety of genetic, genomic, and biomarker data that are currently available to the resea...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 6, 2019 Category: Research Source Type: funding

Conference for Early Stage HIV/AIDS Researchers Using Nonhuman Primate Models (R13 Clinical Trial Not Allowed)
The objectives of the meeting(s) supported by this FOA are to provide these early stage HIV/AIDS researchers with guidance on conducting preclinical research to inform clinical trials on reducing the incidence of HIV/AIDS infection, including vaccine development and testing; developing next-generation HIV therapies, including potential cure therapies; treatment of HIV-associated coinfections, comorbidities and complications; and infection prevention strategies. In addition to guidance on translating results to clinical trials, the conference should target developing skills related to networking, grantsmanship, and goal/mil...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 3, 2019 Category: Research Source Type: funding

HLA and KIR Region Genomics in Immune-Mediated Diseases (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-19-041 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from investigators to participate in the HLA and KIR Region Genomics in Immune Mediated Diseases Consortium (HLARGC). This cooperative research group supports projects defining the association between variations in the human leukocyte antigen (HLA), also known as the Major Histocompatibility Complex (MHC), and natural killer cell immunoglobulin-like receptor (KIR) genetic regions and immune-mediated diseases, including outcomes following cell, tissue, and orga...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 2, 2019 Category: Research Source Type: funding

HLA and KIR Region Genomics in Immune-Mediated Diseases (U19 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-19-044 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from investigators to participate in the HLA and KIR Region Genomics in Immune Mediated Diseases Consortium (HLARGC). This cooperative research group supports projects defining the association between variations in the human leukocyte antigen (HLA), also known as the Major Histocompatibility Complex (MHC), and natural killer cell immunoglobulin-like receptor (KIR) genetic regions and immune-mediated diseases, including outcomes following cell, tissue, and orga...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 2, 2019 Category: Research Source Type: funding

Notice of Correction to PAR-19-223, "Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)"
Notice NOT-DA-19-031 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 12, 2019 Category: Research Source Type: funding

Environmental Influences on Aging: Effects of Extreme Weather and Disaster Events on Aging Populations (R01 Clinical Trial Optional)
Funding Opportunity PAR-19-250 from the NIH Guide for Grants and Contracts. Background The purpose of this funding opportunity announcement is to advance our understanding of the impact of extreme weather and disaster events in aging human populations. Together with the companion FOA (PAR-19-XXX) that focuses on basic mechanisms of aging utilizing animal models, these two FOAs will help to explicate the behavioral, biological, epigenetic, genetic, neurological and socioecological processes that occur during extreme weather or disaster events and that affect aging processes. Through the integration of the population studie...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 12, 2019 Category: Research Source Type: funding

Rare Disease Cohorts in Heart, Lung, Blood and Sleep Disorders (UG3/UH3 Clinical Trial Not Allowed)
Funding Opportunity RFA-HL-20-014 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to fund research centers that will establish longitudinal cohorts in rare HLBS diseases to investigate unaddressed research questions using epidemiologic study designs and methods that are appropriate for conditions affecting fewer than 200,000 persons in the US. These observational cohort studies should be designed to provide an evidence base for future interventional studies, including clinical trials; for developing better diagnostics than those that are currently available; for answering early translational questi...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 4, 2019 Category: Research Source Type: funding

Short-term Mentored Career Enhancement Award in Dental, Oral and Craniofacial Research for Mid-Career and Senior Investigators (K18 Independent Clinical Trial Not Allowed)
Funding Opportunity PAR-19-238 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for short-term mentored career enhancement (K18) awards in dental, oral and craniofacial research with a focus on behavioral and social sciences, and genetic and genomic research. The intent of this program is to provide mid-career or senior investigators with short-term training in the theories, tools, methods or approaches of another scientific area, in order to enhance their existing research program. Two categories of candidates are targeted: (a) established dental, oral, and ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 4, 2019 Category: Research Source Type: funding

Limited Competition Centers of Excellence in Ethical, Legal and Social Implications (ELSI) Research (CEER) (RM1 Clinical Trial Optional)
Funding Opportunity RFA-HG-19-012 from the NIH Guide for Grants and Contracts. National Human Genome Research Institute (NHGRI) is soliciting grant applications for the support of Centers of Excellence in Ethical, Legal and Social Implications (ELSI) Research (CEERs). The CEER Program is designed to support the establishment of sustainable trans-disciplinary research teams with the expertise and flexibility to anticipate, conduct research on, and quickly address a range of cutting edge ethical, legal, and social issues related to genetics and genomics. The Program is intended to create new research opportunities that cros...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 27, 2019 Category: Research Source Type: funding

Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)
Funding Opportunity PAR-19-223 from the NIH Guide for Grants and Contracts. Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 18, 2019 Category: Research Source Type: funding

Notice of Special Interest: Development of Cryogenic or Other Long-term Preservation and Revival Methods for Drosophila and Zebrafish Genetic Stocks
Notice NOT-OD-19-089 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 14, 2019 Category: Research Source Type: funding

Functional Target Validation for Alzheimer's Disease-Related Dementias (ADRDs) (UG3/UH3 Clinical Trial Not Allowed)
Funding Opportunity RFA-NS-19-015 from the NIH Guide for Grants and Contracts. This FOA invites applications that propose the comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer's Disease-Related Dementias (ADRDs). This FOA seeks to promote critical target validation approaches to help de-risk subsequent translational research and accelerate the advancement of novel therapies for ADRD. Target(s) or molecular pathway(s) to be considered for validation must have been already identified using tissue expression or genetic data generated in human samples. In its initial phase, th...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 6, 2019 Category: Research Source Type: funding

Dear Colleague Letter: Genetic Underpinnings for Life in Antarctica (LIA)
Available Formats: HTML: https://www.nsf.gov/pubs/2019/nsf19045/nsf19045.jsp?WT.mc_id=USNSF_25&WT.mc_ev=clickPDF: https://www.nsf.gov/pubs/2019/nsf19045/nsf19045.pdf?WT.mc_id=USNSF_25&WT.mc_ev=clickDocument Number: nsf19045This is an NSF Program Announcements and Information item. (Source: NSF Program Announcements and Information)
Source: NSF Program Announcements and Information - March 1, 2019 Category: Science Source Type: funding

Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R21 Clinical Trial Optional)
Funding Opportunity PA-19-201 from the NIH Guide for Grants and Contracts. The purpose of this FOAs are to encourage mechanistic research to investigate the impact of sleep disturbances on chronic pain. The mechanisms and processes underlying the contribution of sleep disturbances to chronic pain development and maintenance may be very broad. This FOA encourages interdisciplinary collaborations by experts from multiple fieldsneuroscientists, psychologists,endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inqu...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 28, 2019 Category: Research Source Type: funding

Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R01 Clinical Trial Optional)
Funding Opportunity PA-19-200 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fieldsneuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 28, 2019 Category: Research Source Type: funding

Notice of Special Interest to Encourage Resource-Related Research Project Applications for Developing Methods for Cryogenic or Other Long-term Preservation and Revival of Drosophila and Zebrafish Genetic Stocks
Notice NOT-OD-19-081 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 27, 2019 Category: Research Source Type: funding

Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States Including in Health Disparities Populations (U19 Clinical Trial not Allowed)
Funding Opportunity RFA-NS-19-012 from the NIH Guide for Grants and Contracts. The National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA) intend to publish a Funding Opportunity Announcement (FOA) to solicit applications for a large prospective clinical research study to determine the specific subsets of stroke events that predict cognitive impairment and dementia in post-stroke populations in the United States, including in health disparities populations, and what additional clinical factors and comorbidities along the AD/ADRD spectrum may causally synergize with stroke to r...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 15, 2019 Category: Research Source Type: funding

Limited Competition: Mutant Mouse Resource and Research Centers (U42 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-175 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for the continued support and advancement of the Mutant Mouse Resource and Research Centers (MMRRC). The MMRRC consortium is expected to facilitate research by identifying, acquiring, evaluating, characterizing, cryopreserving, and distributing mutant mouse strains to qualified biomedical investigators. A regional network of four MMRRCs and an Informatics, Coordination and Service Center (ICSC) collectively serve the needs of the biomedical research community for transgenic, knockout...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 30, 2019 Category: Research Source Type: funding

High Quality Human Reference Genomes (HQRG) (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-HG-19-002 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute (NHGRI) seeks applications for the production of High Quality Human Reference Genomes (HQRG) as a component of the NHGRI Human Genome Reference Program (HGRP). One aim of the HGRP is to develop a genome reference that is representative of human population genetic diversity. To help achieve this goal, this HQRG initiative is expected to establish metrics for high quality-genome assemblies; collaborate with other HGRC awardees on sample selection and prioritization; produce on the order of 350 haplotyp...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 30, 2019 Category: Research Source Type: funding

Methods Development for Cryogenic or Other Long-term Preservation and Revival of Drosophila and Zebrafish Genetic Stocks (R21 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-176 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) supports exploratory research projects aimed at developing cryogenic or other long-term preservation and revival approaches for Drosophila or zebrafish genetic stocks, which are essential laboratory animal models for biomedical research. The proposed project should address critical knowledge and technology gaps and describe approaches towards the development of reliable, easy-to-use and cost effective cryogenic or other long-term preservation and revival methods for wild-type and mutant strains of Drosop...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 29, 2019 Category: Research Source Type: funding

The KUH Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-18-024 from the NIH Guide for Grants and Contracts. The purpose of the KUH/NIDDK Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to recruit exceptional graduate students who are recognized by their institutions for their high potential and to incentivize them to pursue a Kidney, Urologic or Hematologic (K, U, or H) postdoctoral position that ultimately positions them to become independent K, U, or H researchers. This two-phase award will facilitate completion of the doctoral dissertation and stablize the transition of highly talented Ph.D candidates from a variety of fields, inc...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 28, 2019 Category: Research Source Type: funding

The KUH Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Clinical Trial Not Allowed)
The purpose of the KUH/NIDDK Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to recruit exceptional graduate students who are recognized by their institutions for their high potential and to incentivize them to pursue a Kidney, Urologic or Hematologic (K, U, or H) postdoctoral position that ultimately positions them to become independent K, U, or H researchers. This two-phase award will facilitate completion of the doctoral dissertation and stablize the transition of highly talented Ph.D candidates from a variety of fields, including, but not limited to, engineering, statistics, data science, imaging, bioc...
Source: NIDDK Funding Opportunities - January 28, 2019 Category: Endocrinology Source Type: funding

The KUH Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Clinical Trial Not Allowed)
The purpose of the KUH/NIDDK Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to recruit exceptional graduate students who are recognized by their institutions for their high potential and to incentivize them to pursue a Kidney, Urologic or Hematologic (K, U, or H) postdoctoral position that ultimately positions them to become independent K, U, or H researchers. This two-phase award will facilitate completion of the doctoral dissertation and stablize the transition of highly talented Ph.D candidates from a variety of fields, including, but not limited to, engineering, statistics, data science, imaging, bioc...
Source: NIDDK Funding Opportunities - January 28, 2019 Category: Endocrinology Source Type: funding

Exploring the Mechanisms Underlying Analgesic Properties of Minor Cannabinoids and Terpenes (R21 Clinical Trial Optional)
Funding Opportunity RFA-AT-19-009 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement (FOA), the National Center for Complementary and Integrative Health (NCCIH) solicits grant research applications to study minor cannabinoids and terpenes in the cannabis plant as it relates to pain and nociception. Minor cannabinoids are defined as any and all cannabinoids from the cannabis plant other than ?9-tetrahydrocannabinol (?9-THC). Cannabinoids and terpenes of particular interest include the following: Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC), Myrcene, ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 3, 2019 Category: Research Source Type: funding

Exploring the Mechanisms Underlying Analgesic Properties of Minor Cannabinoids and Terpenes (R01 Clinical Trial Optional)
Funding Opportunity RFA-AT-19-008 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement (FOA), the National Center for Complementary and Integrative Health (NCCIH) solicits grant research applications to study minor cannabinoids and terpenes in the cannabis plant as it relates to pain and nociception. Minor cannabinoids are defined as any and all cannabinoids from the cannabis plant other than ?9-tetrahydrocannabinol (?9-THC). Cannabinoids and terpenes of particular interest include the following: Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC), Myrcene, ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 3, 2019 Category: Research Source Type: funding

Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-104 from the NIH Guide for Grants and Contracts. As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. Whole genome, exome, and transcript...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 14, 2018 Category: Research Source Type: funding

Notice for the All of Us Research Program Genetic Counseling Resource Funding Opportunity and Informational Webinar
Notice NOT-PM-19-001 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 30, 2018 Category: Research Source Type: funding

Genetic Engineering Technologies for HIV Cure Research (U19 Clinical Trial Optional)
Funding Opportunity RFA-AI-18-058 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to apply genetic engineering technologies to HIV-1 cure research. Gene- and/or cell-based approaches are sought that can achieve long term remission of HIV-1 in the absence of antiretroviral treatment or complete elimination of HIV-1. Applications are expected to include basic science/preclinical research as well as translational activities such as test-of-concept studies in animal models or human subjects and must be designed as collaborative efforts between academia and the private...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 29, 2018 Category: Research Source Type: funding

Molecular and Genetic Characterization of Inborn Errors of Immunity (R21 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-079 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics. (Source: NIH Funding Opportuniti...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 26, 2018 Category: Research Source Type: funding

Molecular and Genetic Characterization of Inborn Errors of Immunity (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-078 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics. (Source: NIH Funding Opportuniti...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 26, 2018 Category: Research Source Type: funding

Small Research Grants for Analyses of Data for the Gabriella Miller Kids First Data Resource (R03 - Clinical Trial Not Allowed)
Funding Opportunity PAR-19-069 from the NIH Guide for Grants and Contracts. REISSUE of PAR-18-733 The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The overall goal of the Gabriella Miller Kids First Pediatric Data Resource is to help researchers understand the underlying mechanisms of these conditions, leading to more refined diagnos...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 16, 2018 Category: Research Source Type: funding

Collaborative Study on the Genetics of Alcoholism (COGA) (Clinical Trial Not Allowed U10)
Funding Opportunity RFA-AA-19-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) issued by the National Institute on Alcoholism and Alcohol Abuse (NIAAA), solicits cooperative agreement (U10) applications focusing on studies that (i) identify genetic variants that affect the susceptibility to develop alcohol dependence in adult and adolescent populations, (ii) determine molecular and functional mechanisms of these variants, (iii) identify and characterize gene x gene and gene x environment interactions leading to alcoholism, (iv) develop and refine phenotypes that will facilitate ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 5, 2018 Category: Research Source Type: funding

NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)
Funding Opportunity PAR-19-048 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to use NIH-funded omics capacity to carry out studies of the genetic basis and/or omics signatures of common, complex heart, lung, and blood disorders. Successful applicants will provide biospecimens for whole genome sequencing or other omics assays. No funding will be provided under this FOA. The omics data and related phenotypic data will be deposited in a public database such as dbGaP. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 1, 2018 Category: Research Source Type: funding

Novel Approaches for Relating Genetic Variation to Function and Disease (R43/R44 Clinical Trial Not Allowed)
Funding Opportunity PA-19-043 from the NIH Guide for Grants and Contracts. Genome-wide association studies and other disease studies have identified many variants that are statistically associated with disease risk, disease protection, or other traits. However, such studies do not generally show which specific variants in genomic elements cause these effects, or how they result in differences in function. Similarly, genomic sequencing studies in clinical settings have identified many variants in healthy and diseased individuals. However, the pathogenicity of such variants is often unknown, leading to their classification ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 31, 2018 Category: Research Source Type: funding

Specialized Alcohol Research Centers Clinical Trial Optional (P50 Clinical Trial Optional)
Funding Opportunity RFA-AA-19-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for specialized Alcohol Research Centers using the P50 mechanism. The overall purpose of the NIAAA Alcohol Research Center program is to provide leadership in conducting and fostering interdisciplinary, collaborative research on a wide variety of topics relevant to the Institutes mission. These topics include, but are not limited to: the nature, etiology, genetics, diagnosis, treatment, and prevention of alcohol use disorders and their biomedical, psychosocial, and economic conseq...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 11, 2018 Category: Research Source Type: funding

Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01- Clinical Trial Optional)
Funding Opportunity RFA-DK-18-017 from the NIH Guide for Grants and Contracts. The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified about 200 susceptibility loci for IBD. The IBDGC has recently been awarded renewed funding to identify causal genes and genetic variants within these loci, and to elucidate the mechanisms through which they contribute to the pathophysiology of IBD. However, the IBDGC's current resources permit them to explore the functions of only a limited set of genes within a limited set of physiological domains. T...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 12, 2018 Category: Research Source Type: funding

Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01- Clinical Trial Optional)
The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified about 200 susceptibility loci for IBD. The IBDGC has recently been awarded renewed funding to identify causal genes and genetic variants within these loci, and to elucidate the mechanisms through which they contribute to the pathophysiology of IBD. However, the IBDGC's current resources permit them to explore the functions of only a limited set of genes within a limited set of physiological domains. The purpose of this Funding Opportunity Announcement (FOA) is to expand the numbe...
Source: NIDDK Funding Opportunities - September 12, 2018 Category: Endocrinology Source Type: funding

Communication and Decision Making for Individuals with Inherited Cancer Syndromes (U01 Clinical Trial Optional).
Funding Opportunity RFA-CA-19-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative) that is intended to accelerate cancer research. The purpose of this FOA is to develop, test, and evaluate interventions and implementation approaches, or adapt existing approaches, to improve patient/provider/family risk communication and decision making for individuals and families with an inherited susceptibility to cancer. Specifically, this FOA targets the fol...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 10, 2018 Category: Research Source Type: funding

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
Funding Opportunity PAR-18-913 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Availa...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 7, 2018 Category: Research Source Type: funding

U.S. - India Collaborative Vision Research Program (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-18-912 from the NIH Guide for Grants and Contracts. This funding Opportunity Announcement (FOA) encourages Multiple Principal Investigator (Multi-PD/PI) applications from United States (U.S.) and Indian institution as bilateral collaborations that will advance science and technology important to understanding, preventing, and treating blinding eye diseases, visual disorders, and their complications. Areas of Research Collaboration: Applications are encouraged from organization/institutions that propose to conduct research on the basic biology and/or genetics of ophthalmic diseases through collabora...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 7, 2018 Category: Research Source Type: funding

New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (R01 Clinical Trial Not Allowed)
Funding Opportunity PA-18-908 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex etiologies identified through genome-wide association or sequencing studies. The overarching goal of this initiative is to support the development of innovative computational methods that facilitate the elucidation of the functionality of genetic variants associated with mental illness, taking into ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 29, 2018 Category: Research Source Type: funding